Company Filing History:
Years Active: 2015-2018
Title: Varun Anilkumar Mehta: Innovator in Tyrosine Kinase Inhibitors
Introduction
Varun Anilkumar Mehta is a prominent inventor located in Baroda, India. He has made significant contributions to the field of pharmaceutical research, particularly in the development of innovative compounds that target tyrosine kinases. With two patents to his name, Mehta is recognized for his impactful inventions that have the potential to improve therapeutic treatments.
Latest Patents
Mehta's latest patents are as follows:
1. **Amidoheteroaryl Aroyl Hydrazide Ethynes** - This invention pertains to novel amidoheteroaryl aroyl hydrazide ethynes, which serve as tyrosine kinase inhibitors. The patent details the process of preparing these compounds and their use in developing pharmaceutical compositions aimed at treating disorders related to tyrosine kinases in humans.
2. **Diarylacetylene Hydrazide Containing Tyrosine Kinase Inhibitors** - This patent relates to novel diarylacetylene hydrazide compounds, which also function as tyrosine kinase inhibitors. The document outlines the preparation process for these compounds and their application in formulating pharmaceutical compositions for treating tyrosine kinase-related disorders in warm-blooded animals.
Career Highlights
Varun Anilkumar Mehta works at Sun Pharma Advanced Research Company Limited, where he has contributed his expertise to enhance drug discovery and development processes. His focus on innovative pharmaceutical solutions underscores his dedication to advancing medical treatments.
Collaborations
In his professional journey, Mehta collaborates with notable colleagues such as Hemant Ashvinbhai Chokshi and Sabbirhusen Yusufbhai Chimanwala. These collaborations allow for a diverse exchange of ideas and foster an environment of innovation within the company.
Conclusion
Varun Anilkumar Mehta stands out as an accomplished inventor in the pharmaceutical field. His patents reflect a commitment to advancing healthcare through innovative solutions targeting critical biological pathways. As he continues his work at Sun Pharma Advanced Research Company Limited, Mehta is poised to make even more contributions to the world of medicine.